よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (49 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
122.
Kanra G, Ceyhan M, Ozmert E. Reactogenicity and immunogenicity of a new measles-
mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children. Turk J
Pediatr 2000; 42(4): 275–7.
123.
Gatchalian S, Cordero-Yap L, Lu-Fong M, et al. A randomized comparative trial in order to
assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when
given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health 1999; 30(3):
511–7.
124.
Usonis V, Bakasenas V, Chitour K, Clemens R. Comparative study of reactogenicity and
immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Infection 1998; 26(4): 222–6.
125.
Lee H, Kim HW, Cho HK, Park EA, Choi KM, Kim KH. Reappraisal of MMR vaccines
currently used in Korea. Pediatr Int 2011; 53(3): 374–80.
126.
Kitano T. Close the gap for routine mumps vaccination in Japan. Human Vaccines &
Immunotherapeutics 2021; 17(1): 205–10.
127.
Shah N, Ghosh A, Kumar K, Dutta T, Mahajan M. A review of safety and immunogenicity of
a novel measles, mumps, rubella (MMR) vaccine. Hum Vaccin Immunother 2024; 20(1): 2302685.
128.
Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass
vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization
programs. Am J Epidemiol 2000; 151(5): 524–30.
129.
Tesović G, Begovac J, Baće A. Aseptic meningitis after measles, mumps, and rubella vaccine.
Lancet 1993; 341(8859): 1541.
130.
Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic
49
Kanra G, Ceyhan M, Ozmert E. Reactogenicity and immunogenicity of a new measles-
mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children. Turk J
Pediatr 2000; 42(4): 275–7.
123.
Gatchalian S, Cordero-Yap L, Lu-Fong M, et al. A randomized comparative trial in order to
assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when
given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health 1999; 30(3):
511–7.
124.
Usonis V, Bakasenas V, Chitour K, Clemens R. Comparative study of reactogenicity and
immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
Infection 1998; 26(4): 222–6.
125.
Lee H, Kim HW, Cho HK, Park EA, Choi KM, Kim KH. Reappraisal of MMR vaccines
currently used in Korea. Pediatr Int 2011; 53(3): 374–80.
126.
Kitano T. Close the gap for routine mumps vaccination in Japan. Human Vaccines &
Immunotherapeutics 2021; 17(1): 205–10.
127.
Shah N, Ghosh A, Kumar K, Dutta T, Mahajan M. A review of safety and immunogenicity of
a novel measles, mumps, rubella (MMR) vaccine. Hum Vaccin Immunother 2024; 20(1): 2302685.
128.
Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass
vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization
programs. Am J Epidemiol 2000; 151(5): 524–30.
129.
Tesović G, Begovac J, Baće A. Aseptic meningitis after measles, mumps, and rubella vaccine.
Lancet 1993; 341(8859): 1541.
130.
Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic
49